Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Boris Dominik Juelg, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Boris Juelg and Bruce Walker.
Connection Strength

2.853
  1. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. Lancet HIV. 2019 04; 6(4):e259-e268.
    View in: PubMed
    Score: 0.841
  2. Factors predicting discordant virological and immunological responses to antiretroviral therapy in HIV-1 clade C infected Zulu/Xhosa in South Africa. PLoS One. 2012; 7(2):e31161.
    View in: PubMed
    Score: 0.515
  3. Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers. Clin Infect Dis. 2010 Jul 15; 51(2):233-8.
    View in: PubMed
    Score: 0.461
  4. The paradox of incomplete CD4+ cell count restoration despite successful antiretroviral treatment and the need to start highly active antiretroviral therapy early. Clin Infect Dis. 2009 Mar 15; 48(6):795-7.
    View in: PubMed
    Score: 0.420
  5. Possession of HLA class II DRB1*1303 associates with reduced viral loads in chronic HIV-1 clade C and B infection. J Infect Dis. 2011 Mar 15; 203(6):803-9.
    View in: PubMed
    Score: 0.120
  6. Lack of Duffy antigen receptor for chemokines: no influence on HIV disease progression in an African treatment-naive population. . 2009 May 08; 5(5):413-5; author reply 418-9.
    View in: PubMed
    Score: 0.106
  7. Differential neutralization of human immunodeficiency virus (HIV) replication in autologous CD4 T cells by HIV-specific cytotoxic T lymphocytes. J Virol. 2009 Apr; 83(7):3138-49.
    View in: PubMed
    Score: 0.104
  8. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature. 2016 07 28; 535(7613):556-60.
    View in: PubMed
    Score: 0.044
  9. High avidity CD8+ T cells efficiently eliminate motile HIV-infected targets and execute a locally focused program of anti-viral function. PLoS One. 2014; 9(2):e87873.
    View in: PubMed
    Score: 0.037
  10. Lack of association between HLA class II alleles and in vitro replication capacities of recombinant viruses encoding HIV-1 subtype C Gag-protease from chronically infected individuals. J Virol. 2012 Jan; 86(2):1273-6.
    View in: PubMed
    Score: 0.032
  11. A high-throughput single-cell analysis of human CD8? T cell functions reveals discordance for cytokine secretion and cytolysis. J Clin Invest. 2011 Nov; 121(11):4322-31.
    View in: PubMed
    Score: 0.031
  12. Epithelial adhesion molecules can inhibit HIV-1-specific CD8? T-cell functions. Blood. 2011 May 12; 117(19):5112-22.
    View in: PubMed
    Score: 0.030
  13. HIV-1-specific interleukin-21+ CD4+ T cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function. J Virol. 2011 Jan; 85(2):733-41.
    View in: PubMed
    Score: 0.029
  14. Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat Med. 2010 Oct; 16(10):1147-51.
    View in: PubMed
    Score: 0.029
  15. Impact of select immunologic and virologic biomarkers on CD4 cell count decrease in patients with chronic HIV-1 subtype C infection: results from Sinikithemba Cohort, Durban, South Africa. Clin Infect Dis. 2009 Sep 15; 49(6):956-64.
    View in: PubMed
    Score: 0.027
  16. The Duffy antigen receptor for chemokines null promoter variant does not influence HIV-1 acquisition or disease progression. . 2009 May 08; 5(5):408-10; author reply 418-9.
    View in: PubMed
    Score: 0.027
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.